Clinical variability of haemophilia A and B in Mexican families by factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T/A1298C

Haemophilia

Volumn 15, Issue 6, 2009, Pages 1342-1345

  Lopez Jimenez J J ^a,b   Beltran Miranda C P ^b   Mantilla Capacho, J M ^b   Esparza Flores, M A ^c   Lopez Gonzalez L C ^a   Jaloma Cruz, A R ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYTOSINE; GUANOSINE; METHYLENETETRAHYDROFOLIC ACID; PROTHROMBIN; THYMINE;

ADOLESCENT; ADULT; BLEEDING; BLOOD CLOTTING TIME; CHILD; DISEASE SEVERITY; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LETTER; MAJOR CLINICAL STUDY; MEXICO; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUBSTITUTION THERAPY; SYMPTOMATOLOGY; THROMBOSIS;

FACTOR V; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MEXICO; MUTATION; PROTHROMBIN;

EID: 70449584734     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02069.x     Document Type: Letter

References (11)

1. Shetty S, Vora S, Kulkarni B. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007, 138:541-4.
2. Nichols WC, Amano K, Cacheris PM. Moderation of haemophilia A phenotype by the factor V R506Q mutation. Blood 1996, 88:1183-7.
3. Tizzano EF, Soria JM, Coll I. The prothrombin 20210A allele influences clinical manifestations of haemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002, 87:279-85.
4. Kurnik K, Kreuz W, Horneff S. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe haemophilia A in children--results of a multicenter study. Haematologica 2007, 92:982-5.
5. Van Dijk K, Van der Bom JG, Fischer K. Do prothrombotic factors influence clinical phenotype of severe haemophilia?. A review of the literature. Thromb Haemost 2004, 92:305-10.
6. Pruthi RK, Heit JA, Green MM. Venous thromboembolism after hip fracture surgery in a patient with hemophilia B and factor V Arg 506 Gln (factor V Leiden). Haemophilia 2000, 6:631-4.
7. Ripoll L, Paulin D, Thomas S, Drouet LO. Multiplex PCR-mediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997, 78:960-1.
8. Frosst P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111-3.
9. Van der Put NM, Gabreëls F, Stevens EM. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 1998, 62:1044-51.
10. Ahmed R, Kannan M, Choudhry VP, Saxena R. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?. Thromb Res 2003, 109:71-2.
11. Dávalos IP, Olivares N, Castillo MT. The C677T polymorphism of the methylenetetrahydrofolate reductase gene in Mexican mestizo neural-tube defect parents, control mestizo and native populations. Ann Genet 2000, 43:89-92.